How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) issued its earnings results on Wednesday, November, 10th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.07. The business earned $0.34 million during the quarter, compared to analysts' expectations of $2.67 million.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM) , Dynavax Technologies (DVAX) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Viking Therapeutics (VKTX) , Selecta Biosciences (SELB) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Vaxart (VXRT) and Agile Therapeutics (AGRX) .

When did PhaseBio Pharmaceuticals IPO?

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PHAS

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

→ Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad)

Free PHAS Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: 848,888 shs
Market Capitalization: $3.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Insider Trades SEC Filings Social Media Sustainability

Get PhaseBio Pharmaceuticals alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Ad Crypto 101 Media

SHOCKING Crypto Leak…

Claim your free seat by clicking here now.

PHAS Stock News Headlines

December 14, 2023 | finance.yahoo.com

Velia Therapeutics Appoints Michael York as Chief Business Officer

June 5, 2023 | finance.yahoo.com

Alcami Announces CEO Transition

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

May 12, 2023 | marketwatch.com

8-K: PhaseBio Pharmaceuticals Inc

March 31, 2023 | finanznachrichten.de

Absci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

March 31, 2023 | finanznachrichten.de

BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

March 31, 2023 | finance.yahoo.com

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

March 22, 2023 | marketwatch.com

Cardiomyopathy Medication Market Size and Forecast till 2031

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

February 28, 2023 | marketwatch.com

Cardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries Data

January 17, 2023 | benzinga.com

SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals

January 5, 2023 | bizjournals.com

Bankruptcy court approves PhaseBio's $32.9M asset transfer deal

November 8, 2022 | marketwatch.com

Bankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assets

November 4, 2022 | benzinga.com

Short Volatility Alert: PhaseBio Pharmaceuticals, Inc.

November 2, 2022 | msn.com

Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session

November 1, 2022 | msn.com

Why Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket

October 27, 2022 | benzinga.com

PhaseBio Pharmaceuticals 10% Owner Trades Company's Stock

October 25, 2022 | wsj.com

PhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuit

October 25, 2022 | bizjournals.com

PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100M

October 24, 2022 | nasdaq.com

PhaseBio Pharma Files For Chapter 11 Bankruptcy Protection

October 24, 2022 | finance.yahoo.com

PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code

October 24, 2022 | finance.yahoo.com

PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $60M

October 24, 2022 | finance.yahoo.com

PhaseBio Files for Bankruptcy With Plans to Sell Assets

October 19, 2022 | bizjournals.com

Cash-strapped PhaseBio sued by drug development partner in dispute over experimental therapy

October 6, 2022 | finance.yahoo.com

PhaseBio Might Have To Return Global Rights To Its Lead Program

October 3, 2022 | finance.yahoo.com

Hypertension Clinical Trials Pipeline Analysis: 90+ Companies are Working to Improve the Treatment Space | DelveInsight

September 29, 2022 | finance.yahoo.com

Why an East Bay company wants control of its partner's blood thinner antidote

See More Headlines

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/18/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PHAS
CUSIP: N/A
CIK: 1169245
Web: www.phasebio.com
Phone: (610) 981-6500
Fax: N/A
Employees: 60
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-131,070,000.00
Net Margins: -12,572.13%
Pretax Margin: -12,572.13%
Return on Equity: N/A
Return on Assets: -174.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.47
Quick Ratio: 0.47

Sales & Book Value

Annual Sales: $818,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.93) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 49,858,000
Free Float: 44,922,000
Market Cap: $3.50 million
Optionable: Not Optionable
Beta: 2.57

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Jonathan P. Mow
Chief Executive Officer & Director
John P. Sharp
Chief Financial Officer
John S. Lee
Chief Medical Officer
Kristopher L. Hanson
Secretary, Senior VP & General Counsel
Susan E. Arnold
Senior Vice President-Technical Operations

Key Competitors

View All Competitors

PHAS Stock Analysis - Frequently Asked Questions

How were PhaseBio Pharmaceuticals' earnings last quarter?: PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) issued its earnings results on Wednesday, November, 10th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.07. The business earned $0.34 million during the quarter, compared to analysts' expectations of $2.67 million.
What other stocks do shareholders of PhaseBio Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).
When did PhaseBio Pharmaceuticals IPO?: PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.
How do I buy shares of PhaseBio Pharmaceuticals?: Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHAS) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

PHAS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PHAS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info